IL-31 MONOCLONAL ANTIBODIES
First Claim
1. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:
- 2, wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having ATCC Patent Deposit Designation PTA-6815, wherein the third complementarity determining region (CDR) of the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO;
53, and the third CDR of the light chain variable domain consists of the amino acid sequence of SEQ ID NO;
56.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.
9 Citations
10 Claims
-
1. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:
- 2, wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having ATCC Patent Deposit Designation PTA-6815, wherein the third complementarity determining region (CDR) of the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO;
53, and the third CDR of the light chain variable domain consists of the amino acid sequence of SEQ ID NO;
56. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 2, wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having ATCC Patent Deposit Designation PTA-6815, wherein the third complementarity determining region (CDR) of the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO;
Specification